香蕉直播

The purpose of the trial is to look at the short-term (10 day)聽effects of a medication, already approved in Australia (not for PWS), on the brain GABA levels in people with Prader Willi Syndrome (PWS) compared to typically developing people. This medication has been trialled in many studies, has a good safety profile for use with healthy people, and is approved for use and regularly prescribed to treat alcohol withdrawal.

Participants will be invited to complete:

• two clinic visits (2.5 hrs each)
• 10-day course of the drug
• two MRI scans
• one blood draw
• You will receive two $50 vouchers, one for each clinical visits, and may be reimbursed for any reasonable travel, parking, meals and other expenses associated with the research project visit.

You may be reimbursed for any reasonable travel, parking, meals and other expenses associated with the research project visit.

You may be eligible to participate in this study if you:

• are aged 18 to 30 years
• have no known neurological, psychiatric, neurogenetic or serious medical condition
  

You will not be able to participate in this study if you:

• Are pregnant or breastfeeding
• Have any MRI contraindications
• Have a known neurological, psychiatric, neurogenetic or serious medical condition
• Are currently receiving treatment with a GABA compound
• Have been using or have had a change in the dose of a non-GABA compound medication in the 4 weeks prior to participation.
• Have evidence of renal failure
• Have severe hepatic failure
• Have a known sulphite hypersensitivity

If you are interested in assisting with this important and exciting area of research, please contact the study facilitator:

Phone: 02 8627 6048
Email: clinicaltrials.boden@sydney.edu.au

Contacting us for additional information does not obligate you to participate in the study.聽